Information letter to health care professionals regarding the medicinal product CASGINA. Caspofungin: the use of polyacrylonitrile (PAN) membranes during continuous renal replacement therapy is not recommended

04.02.2026 311 views

Інформаційний лист-звернення до спеціалістів системи охорони здоров’я щодо лікарського засобу КАСГІНА. Каспофунгін (caspofungin): не рекомендується застосування мембран з поліакрилонітрилу (PAN) під час безперервної ниркової замісної терапіїPDF · 120 КБ

Завантажити

Information letter to health care professionals regarding the medicinal product CASGINA. Caspofungin: the use of polyacrylonitrile (PAN) membranes during continuous renal replacement therapy is not recommended

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter to health care professionals regarding the medicinal product CASGINA. Caspofungin: the use of polyacrylonitrile (PAN) membranes during continuous renal replacement therapy is not recommended

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration